TYK Medicines (2410) Receives Approval for 4.61 Million H-Share Conversion

Bulletin Express

Feb 12

TYK Medicines, Inc. (浙江同源康醫藥股份有限公司, stock code: 2410) obtained listing approval from The Stock Exchange of Hong Kong Limited on February 11, 2026, for the conversion of 4.61 million unlisted shares into H shares. These shares represent about 1.21% of the company’s total issued share capital.

Upon completion of the conversion, TYK Medicines will have 380.07 million H shares, compared to the previous structure of 375.46 million H shares and 4.61 million unlisted shares. This move enables full circulation of the company’s H shares, and relevant conversion and trading procedures will be finalized in accordance with regulatory requirements. Shareholders and investors are advised to monitor official updates for further details.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163699431"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163699431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163699431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163699431","market":"hk","top_or_hot":-1,"title":"TYK Medicines (2410) Receives Approval for 4.61 Million H-Share Conversion","media":"Bulletin Express","content":"<p>TYK Medicines, Inc. (浙江同源康醫藥股份有限公司, stock code: 2410) obtained listing approval from The Stock Exchange of Hong Kong Limited on February 11, 2026, for the conversion of 4.61 million unlisted shares into H shares. These shares represent about 1.21% of the company’s total issued share capital.</p>\n<p>Upon completion of the conversion, TYK Medicines will have 380.07 million H shares, compared to the previous structure of 375.46 million H shares and 4.61 million unlisted shares. This move enables full circulation of the company’s H shares, and relevant conversion and trading procedures will be finalized in accordance with regulatory requirements. Shareholders and investors are advised to monitor official updates for further details.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines (2410) Receives Approval for 4.61 Million H-Share Conversion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines (2410) Receives Approval for 4.61 Million H-Share Conversion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-12 17:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK Medicines, Inc. (浙江同源康醫藥股份有限公司, stock code: 2410) obtained listing approval from The Stock Exchange of Hong Kong Limited on February 11, 2026, for the conversion of 4.61 million unlisted shares into H shares. These shares represent about 1.21% of the company’s total issued share capital.</p>\n<p>Upon completion of the conversion, TYK Medicines will have 380.07 million H shares, compared to the previous structure of 375.46 million H shares and 4.61 million unlisted shares. This move enables full circulation of the company’s H shares, and relevant conversion and trading procedures will be finalized in accordance with regulatory requirements. Shareholders and investors are advised to monitor official updates for further details.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"","article_id":"1163699431","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163699431","pubTimestamp":1770888355,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TYK Medicines, Inc. (浙江同源康醫藥股份有限公司, stock code: 2410) obtained listing approval from The Stock Exchange of Hong Kong Limited on February 11, 2026, for the conversion of 4.61 million unlisted shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02410":"同源康医药-B"},"translate_title":"泰克医药(2410)461万股H股转换获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":1},"content_text":"TYK Medicines, Inc. (浙江同源康醫藥股份有限公司, stock code: 2410) obtained listing approval from The Stock Exchange of Hong Kong Limited on February 11, 2026, for the conversion of 4.61 million unlisted shares into H shares. These shares represent about 1.21% of the company’s total issued share capital.\nUpon completion of the conversion, TYK Medicines will have 380.07 million H shares, compared to the previous structure of 375.46 million H shares and 4.61 million unlisted shares. This move enables full circulation of the company’s H shares, and relevant conversion and trading procedures will be finalized in accordance with regulatory requirements. Shareholders and investors are advised to monitor official updates for further details.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}